Failure to Improve Parameters of Lactose Maldigestion using the Multiprobiotic Product VSL3 in Lactose Maldigesters: A Pilot Study

Yesovitch, Rose; Cohen, Albert; Szilagyi, Andrew

doi:10.1155/2004/417653

Cited by 17 publications

(6 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The contrary situation also occurs. In a previous study in lactose malabsorbers, clinical adaptive characteristics could not be reproduced by feeding the multispecies probiotic VSL3 [52]. A similar outcome with other probiotics was reported in two other studies [53,54].…”

Section: Fig 1 Asupporting

confidence: 67%

Fructose Malabsorption May Be Gender Dependent and Fails to Show Compensation by Colonic Adaptation

et al. 2007

Self Cite

View full text Add to dashboard Cite

Fructose malabsorption is linked to gastrointestinal and other unusual symptoms. Polymers of fructose are also recognized prebiotics. While some prebiotics can self-adapt when consumed regularly (resulting in decreased breath hydrogen and symptoms), we wondered whether self-adaptation occurs with basic fructose. We evaluated 90 subjects (61 females). Each completed a diet questionnaire and underwent a fructose challenge. Breath hydrogen and quantified symptom scores were recorded. Group comparisons for sum of breath hydrogen and total symptom scores were evaluated with the Mann-Whitney U test. Spearman's correlation coefficient and chi(2) or Fisher's exact test were used as appropriate. Malabsorption occurred in 29 patients (32.2%) and low-grade symptoms without malabsorption in 30 (33%). Women complained of symptoms more frequently (p = 0.04) and exhibited more fructose malabsorption (p = 0.0527). Breath hydrogen correlated with symptoms (r = 0.516, p = 0.0037). Adaptation with increasing pretest fructose intake was absent. We conclude that gender may influence fructose malabsorption and there is no adaptation to regular consumption.

show abstract

Section: Fig 1 Asupporting

confidence: 67%

Fructose Malabsorption May Be Gender Dependent and Fails to Show Compensation by Colonic Adaptation

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…Beneficial effects can be caused by microbial β‐galactosidase, a delayed GI transit time, a reduced sensitivity to symptoms and positive effects on intestinal functions and the colonic microbiota 125 . An improvement in parameters for lactose maldigestion has been found by some authors, 126–128 but not by others 129–131 . Recently Levri et al.…”

Section: Helicobacter Pylori Eradication Constipation and Lactose Mamentioning

confidence: 99%

“…125 An improvement in parameters for lactose maldigestion has been found by some authors, [126][127][128] but not by others. [129][130][131] Recently Levri et al 132 reviewed controlled studies only and concluded that probiotic supplementation in general did not alleviate symptoms and signs of lactose intolerance but some evidence was found that specific strains might be effective.…”

Section: Helicobacter Pylori Eradication Constipation and Lactose Mamentioning

confidence: 99%

Review article: probiotics in gastrointestinal and liver diseases

Jonkers

Stockbrügger

2007

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Probiotics, defined as live micro‐organisms with beneficial effects for the host, are widely applied in gastrointestinal and liver diseases. Aim and method To review the available evidence of clinical trials on probiotics in gastrointestinal and liver diseases, with a major focus on irritable bowel syndrome, inflammatory bowel disease, pancreatitis and chronic liver diseases. Results Evidence for the therapeutic or preventive application of particular probiotic strains is available for antibiotic‐associated diarrhoea, rota‐virus‐associated diarrhoea and pouchitis. Results are encouraging for irritable bowel syndrome, ulcerative colitis and for reducing side effects by Helicobacter pylori eradication therapies, but are less clear for Crohn’s disease, lactose intolerance and constipation. In general, for most of these patient groups, more placebo‐controlled methodologically well‐designed studies that pay attention to both clinical outcome and mechanistic aspects are required. The application in liver disease and pancreatitis is promising, but more human trials have to be awaited. Possible mechanisms of probiotics include modulation of the intestinal microbiota and the immune system, but different bacterial may have different effects. Conclusion Further insight into disease entities and the functioning of probiotic strains is required to be able to select disease‐specific strains, which have to be tested in well‐designed placebo‐controlled studies.

show abstract

“…The sample size (48 patients) and study design (randomized, placebo-controlled, single-blind) are important strengths of the study, as most of the previous studies assessing the effect of probiotics on lactose intolerance enrolled fewer patients or were nonrandomized. 11,20,[24][25][26][27] Statistical significance was robustly validated in ITT and PP populations, as well as after adjusting for baseline imbalances as recommended by the EMA guideline. 19 The study was powered to detect an effect on the total symptom score.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of i3.1 Probiotic on Improvement of Lactose Intolerance Symptoms

Cano-Contreras

Alfaro

López

et al. 2020

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

The aim of this study was to assess the efficacy of probiotic i3.1 in improving lactose intolerance symptoms compared with placebo after 8 weeks of treatment.Background: Probiotics are promising strategies to prevent and improve lactose intolerance symptoms, but previous studies have provided conflicting results.Materials and Methods: This randomized, prospective, placebocontrolled study was conducted at the Hospital Juárez de México. We recruited adult patients with lactose intolerance confirmed by a lactose hydrogen breath test (LHBT) ≥ 20 parts per million (ppm) and a lactose intolerance symptom score ≥ 6 both upon lactose challenge. We compared the change from baseline in the scores of a validated symptom questionnaire and the LHBT after 8 weeks of probiotic or placebo treatment.Results: We included 48 patients: 33 receiving the probiotic and 15 receiving placebo (2:1 randomization). Demographic characteristics were homogeneous between groups. The reduction in total symptom score after a lactose challenge was significantly higher in the probiotic group versus the placebo group (−5.11 vs. −1.00; P < 0.001). All the subscores significantly decreased from baseline in the probiotic group, except for vomiting, with significant differences between the probiotic and placebo groups for abdominal pain (P = 0.045) and flatulence (P = 0.004). The area under the curve of the LHBT was significantly reduced from baseline in the probiotic group (P = 0.019), but differences between groups were not significant (P = 0.621). Adverse events were mild without differences between groups, and no serious adverse event was registered.Conclusion: The i3.1 probiotic was safe and efficacious in reducing lactose intolerance symptoms in patients with lactose intolerance, but did not change the LHBT.

show abstract

Failure to Improve Parameters of Lactose Maldigestion using the Multiprobiotic Product VSL3 in Lactose Maldigesters: A Pilot Study

Cited by 17 publications

References 34 publications

Fructose Malabsorption May Be Gender Dependent and Fails to Show Compensation by Colonic Adaptation

Fructose Malabsorption May Be Gender Dependent and Fails to Show Compensation by Colonic Adaptation

Review article: probiotics in gastrointestinal and liver diseases

Efficacy of i3.1 Probiotic on Improvement of Lactose Intolerance Symptoms

Contact Info

Product

Resources

About